

TO: <b>Mail Stop 8</b> <b>Director of the U.S. Patent and Trademark Office</b> <b>P.O. Box 450</b> <b>Alexandria, VA 22304-0450</b>	<b>REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK</b>
--	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court for the **NORTHERN DISTRICT OF CALIFORNIA** on the following

☐ Trademarks or ☒ Patents. ( ☐ the patent action involves 35 U.S.C. § 292.);

DOCKET NO.	DATE FILED	U.S. DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA
PLAINTIFF GENENTECH and ROCHE PALO ALTO, LLC		DEFENDANT APOTEX INC.
		<b>CV 11 24 10</b>
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 6,083,953	7/4/2000	Roche Palo Alto
2		
3		
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY	<input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT
--------------------

CLERK <b>RICHARD W. WIEYING</b>	(BY) DEPUTY CLERK <b>JESSIE MOSLEY</b>	DATE <b>MAY 19 2011</b>
------------------------------------	---	----------------------------

STEPHEN S. RABINOWITZ  
srabinowitz@friendfrank.com  
RANDY C. EISENSMITH (*Pro Hac Vice Pending*)  
randy.eisensmith@friedfrank.com  
FRIED, FRANK, HARRIS, SHRIVER  
& JACOBSON LLP  
ONE NEW YORK PLAZA  
NEW YORK, NEW YORK 10001  
Telephone: 212-859-8000  
Facsimile: 212-859-4000

DURIE TANGRI LLP  
DARALYN J. DURIE (SBN 169825)  
ddurie@durietangri.com  
JOSHUA H. LERNER (SBN 220755)  
jlerner@durietangri.com  
GENEVIEVE P. ROSLOFF (SBN 258234)  
grosloff@durietangri.com  
217 Leidesdorff Street  
San Francisco, CA 94111  
Telephone: 415-362-6666  
Facsimile: 415-236-6300

Attorneys for Plaintiffs  
GENENTECH, INC. and  
ROCHE PALO ALTO LLC

UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF CALIFORNIA

**CV 11 2410**

GENENTECH, INC. and  
ROCHE PALO ALTO LLC,

Plaintiffs,

v.

APOTEX INC.

Defendant.

Case No.

**COMPLAINT**

Plaintiffs Genentech, Inc. and Roche Palo Alto LLC, by their attorneys, for their Complaint in this action allege:

## PARTIES

1. Genentech, Inc. ("Genentech") is a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 1 DNA Way, South San Francisco, California 94080-4990.

2. Roche Palo Alto LLC ("Roche Palo Alto") is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at 3431 Hillview Avenue, Palo Alto, California 94304-1397.

3. On information and belief, Apotex Inc. ("Apotex") is a company organized and existing under the laws of Canada, having a place of business at 150 Signet Drive, Toronto, Ontario, Canada.

## JURISDICTION

4. This action arises under the Patent Act of 1952, as amended, 35 U.S.C. §§ 1-376.

5. This Court has subject matter jurisdiction to hear this action under 28 U.S.C. §§ 1331 and 1338(a).

### INTRADISTRICT ASSIGNMENT

6. For purposes of intradistrict assignment pursuant to Civil Local Rules 3-2(c) and 3-5(b), this Intellectual Property Action is to be assigned on a district-wide basis.

## THE PATENT IN SUIT

7. On July 4, 2000, the United States Patent and Trademark Office issued U.S. Patent No. 6,083,953 (the "953 patent"), entitled "2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol Derivative." Roche Palo Alto is the owner by assignment of all right, title and interest in the '953 patent. A copy of the '953 patent is attached hereto as Exhibit A.

8. Genentech markets and sells an FDA-approved pharmaceutical product, called VALCYTE®, in the form of tablets containing 450 mg of the active pharmaceutical ingredient, valganciclovir hydrochloride in crystalline form. The '953 patent is listed in the FDA's publication of approved drugs, Approved Drug Products with Therapeutic Equivalence Evaluations (known as the "Orange Book"), as covering VALCYTE® 450 mg tablets and their use.

## APOTEX'S ANDA AND NOTICE LETTER

9. By letter to Roche Palo Alto and certain of its affiliates dated April 6, 2011 (the "Notice Letter"), Apotex gave notice under Section 505(j)(2)(B) of the Food, Drug and Cosmetic Act ("FDCA") that it had submitted Abbreviated New Drug Application ("ANDA") No. 202785 to the FDA, seeking the FDA's approval to manufacture, use and sell valganciclovir hydrochloride 450 mg tablets prior to expiration of the '953 patent.

10. In the Notice Letter, Apotex notified Roche Palo Alto that its ANDA contained a "Paragraph IV Certification" that the claims of the '953 patent will not be infringed by the commercial manufacture, use, offer for sale and sale of certain valganciclovir hydrochloride 450 mg tablets (the "Apotex Generic Product"). The Apotex Notice Letter asserts that such commercialization will not infringe the '953 patent because the Apotex Generic Product purportedly will comprise "amorphous," rather than crystalline, valganciclovir hydrochloride.

11. In truth and in fact, amorphous valganciclovir hydrochloride is hygroscopic and prone to conversion to crystalline form during use by patients, e.g. upon exposure to ambient conditions of temperature and humidity.

12. Apotex has provided Roche Palo Alto and its affiliates with confidential access to a portion of its ANDA but has refused to provide physical samples of the Apotex Generic Product and related materials for testing.

13. On information and belief, Apotex threatens to market and sell the Apotex Generic Product in California and elsewhere in the United States and thereby to cause massive infringement of the '953 patent in California, in this district, and elsewhere in the United States.

14. On information and belief, Apotex is not qualified to do business in any State of the United States. On information and belief, Apotex is not subject to jurisdiction in any state court of general jurisdiction in the United States. On information and belief, Apotex derives substantial revenue from sales of pharmaceutical products in California, in this district, and elsewhere in the United States.

15. This complaint is being filed before the expiration of forty-five days from the date Roche Palo Alto and its affiliates received the Apotex Notice Letter.

**FIRST CLAIM FOR RELIEF  
INFRINGEMENT OF THE '953 PATENT**

16. Each of the preceding paragraphs 1 to 15 is incorporated herein as if set forth in full.

17. Plaintiffs believe and expect that following receipt of relevant Apotex physical materials, investigation will confirm that the valganciclovir hydrochloride active ingredient in the proposed Apotex Generic Product will comprise or convert to crystalline valganciclovir hydrochloride at least during use by patients, e.g. upon exposure to ambient atmospheric humidity during storage in pill trays.

18. On information and belief, Apotex's commercial use, offer for sale, and sale of the proposed Apotex Generic Product would infringe the '953 patent at least under 35 U.S.C. §§ 271(b) and (c).

19. On information and belief, Apotex infringed the '953 patent under 35 U.S.C. § 271(e)(2) by filing ANDA No. 202785.

**SECOND CLAIM FOR RELIEF  
DECLARATORY AND EQUITABLE RELIEF  
AGAINST THREATENED PATENT INFRINGEMENT**

20. Each of the preceding paragraphs 1 to 19 is incorporated herein as if set forth in full.

21. Apotex has proposed and threatens to market, sell, and actively induce use of the Apotex Generic Product throughout the United States including in California and this federal judicial district.

22. On information and belief, Apotex's proposed and threatened use, offer for sale, and sale of the Apotex Generic Product will infringe or actively induce or contribute to infringement of the '953 patent.

23. An actual controversy exists between Plaintiffs and Apotex concerning whether offer for sale, sale, or use of the Apotex Generic Product in the United States will infringe the '953 patent.

24. Offer for sale, sale or use of the Apotex Generic Product in the United States would cause injury to Plaintiffs for which there is no adequate remedy at law.

**PRAYER FOR RELIEF**

WHEREFORE Plaintiffs pray that the Court:

(i) declare, adjudge, and decree that Apotex has infringed the '953 patent by submitting ANDA No. 202785;

(ii) declare, adjudge, and decree that Apotex's commercial use, offer for sale and sale of the Apotex Generic Product will infringe the '953 patent;

(iii) issue an Order pursuant to 35 U.S.C. § 271(e)(4)(A) that the effective date of any FDA approval of the Apotex Generic Product be no earlier than the expiration date of the '953 patent, or any later expiration of exclusivity to which Roche Palo Alto is or becomes entitled;

(iv) issue a permanent injunction, pursuant to 35 U.S.C. § 271(e)(4)(B), 35 U.S.C. § 283, and 28 U.S.C. § 1331 restraining and enjoining Apotex and its officers, agents, attorneys and employees, and those acting in privity or concert with them, from engaging in commercial activity that would directly or indirectly infringe the '953 patent; and


(v) award such other and further relief as the Court may deem just and proper.

Dated: May 17, 2011

STEPHEN S. RABINOWITZ  
RANDY C. EISENSMITH  
FRIED, FRANK, HARRIS, SHRIVER  
& JACOBSON LLP

DARALYN J. DURIE  
JOSHUA H. LERNER  
GENEVIEVE P. ROSLOFF  
DURIE TANGRI LLP

By:

  
JOSHUA H. LERNER

Attorneys for Plaintiffs  
GENENTECH INC. and  
ROCHE PALO ALTO LLC